Marker Therapeutics, Inc.

Monthly Archives: October 2018

Marker Therapeutics, Inc. Announces New Executive Appointments

“We are excited and fortunate to have these four highly accomplished professionals join our team,” commented Marker Therapeutics’ President & CEO Peter L. Hoang.

Read More

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 18th begins trading under the ticker (NASDAQ: MRKR), retiring TapImmune’s ticker (TPIV).

Read More

Marker to Present at Two Upcoming Cellular Therapy Conferences

Marker Therapeutics, Inc. President and CEO, Peter L. Hoang, will be participating in conferences next week.

Read More

TapImmune and Marker Therapeutics Announce Successful Closing of Previously Announced Merger and Financing

“The closing of this merger marks a significant milestone, since the combined company is well-positioned to become a leader in cancer immunotherapy, with potentially transformative therapies,” said Peter Hoang, CEO of Marker Therapeutics, Inc.

Learn more about Marker Therapeutics, Inc. by going to

Read More

Mayo Clinic Lands $11 Million Grant to Study Breast Cancer Immunotherapy

The Department of Defense awarded more than $11 million for this Jacksonville study.

Read More

TapImmune’s HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant

Peter L. Hoang, President and CEO of TapImmune, stated, “I am delighted that the U.S. Department of Defense has again chosen to support our technology and therapeutic platform with another funding commitment.

Read More

TapImmune to Present at Two Upcoming Investor Conferences

Peter L. Hoang will be presenting at the 2018 Cantor Global Healthcare Conference and the Sachs Associates 18th Annual Biotech in Europe Forum. Webcast will be available for both events.

Read More